Latest News

Alexis Thompson, MD, MPH
bluebird bio’s Transfusion-Dependent β-Thalassemia Gene Therapy Beti-Cel Continues to Demonstrate Curative Potential in Long-Term Follow-Up Data

December 9th 2024

Protocol-defined transfusion independence (TI) was achieved by 52 of the 63 patients in long-term follow-up study LTF-303.

stem cell
Allogeneic Hematopoietic Stem Cell Transplantation Replicates Posititve Outcomes in Transfusion-Dependent Thalassemia

December 8th 2024

Alaa Ali, MD, from the Lombardi Comprehensive Cancer Center, Georgetown University
Bendamustine Is an Effective Alternative to Fludarabine-Based Lymphodepletion in LBCL

December 7th 2024

Armin Ghobadi, MD, Division of Oncology, Washington University School of Medicine.
Tabelecleucel Efficacy Sustained in EBV-positive PTLD, as FDA Considers Application

December 7th 2024

Nirav N. Shah, MD, Division of Hematology & Oncology, Medical College of Wisconsin
Tandem CD20/CD19 CAR Zamto-Cel Shows Promise in DLBCL

December 7th 2024

Video Interviews

Conference Coverage

View All
Alexis Thompson, MD, MPH
bluebird bio’s Transfusion-Dependent β-Thalassemia Gene Therapy Beti-Cel Continues to Demonstrate Curative Potential in Long-Term Follow-Up Data

December 9th 2024

stem cell
Allogeneic Hematopoietic Stem Cell Transplantation Replicates Posititve Outcomes in Transfusion-Dependent Thalassemia

December 8th 2024

Alaa Ali, MD, from the Lombardi Comprehensive Cancer Center, Georgetown University
Bendamustine Is an Effective Alternative to Fludarabine-Based Lymphodepletion in LBCL

December 7th 2024

Armin Ghobadi, MD, Division of Oncology, Washington University School of Medicine.
Tabelecleucel Efficacy Sustained in EBV-positive PTLD, as FDA Considers Application

December 7th 2024

All News

© 2024 MJH Life Sciences

All rights reserved.